Healthcare Review: ProPhase Labs Inc, Neurocrine Biosciences, Optimer Pharmaceuticals, VIVUS, Rockwell Medical Print E-mail
By Staff and Wire Reports   
Tuesday, 05 February 2013 15:08
U.S. stocks advanced, rebounding from the biggest loss of the year for benchmark indexes, as earnings topped forecasts and Dell (NASDAQ:DELL) Inc. agreed to be taken private in the largest leveraged buyout since the financial crisis.

The S&P 500 has rallied 6 percent in 2013 as U.S. lawmakers reached a budget compromise and companies reported better-than- estimated earnings. The gauge is 3.4 percent below the record 1,565.15 it reached in October 2007. The Dow is 1.2 percent from its all-time high.

Following are the notable movers at mid-day on Tuesday:

ProPhase Labs Inc. (NASDAQ:PRPH)
shares declined 12.35% to $1.49 in the morning hour after Matrixx Initiatives, Inc., the maker of the ZicamĀ® cold, sinus and allergy line of products, announced today that it has withdrawn the $1.60 per share offer it made in October to acquire all of the outstanding shares of ProPhase Labs, Inc. (PRPH).

Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
shares climbed 9.83% to $10.27. The company, on Feb. 1, announced that the Company will report its fourth quarter and year-end 2012 financial results before the Nasdaq market opens on Friday, February 8, 2013. Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Friday morning, February 8, 2013 at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time).

Optimer Pharmaceuticals, Inc. (NASDAQ:OPTR)
stock jumped 5.78% to $10.25 after the company announced that on January 31, 2013 the Inducement Award Sub-Committee of the Compensation, Nominating, and Corporate Governance Committee of its Board of Directors approved the grant of inducement restricted stock units covering an aggregate of 6,240 shares of common stock to 4 new employees.

VIVUS, Inc. (NASDAQ:VVUS)
shares climbed 4.70% to $12.73. The company, on Jan. 7, said prescriptions for obesity drug Qsymia, its main product, rose nearly 68% in the month ended December 21 compared with the preceding four weeks, well above industry forecasts. The drugmaker said it shipped 12,978 prescriptions of Qsymia in the latest period, up from 7,749 in the four weeks ended November 23. New Qsymia prescriptions totaled 5,229 in the latest period.

Rockwell Medical Inc. (NASDAQ:RMTI)
stock fell 5.06% to $6 after  the company yesterday announced successful topline results from the PRIME clinical study of Soluble Ferric Pyrophosphate (SFP), its investigational iron-delivery drug currently in Phase 3 clinical studies for the treatment of iron deficiency in hemodialysis patients. The PRIME study demonstrated that regular administration of SFP-iron via dialysate reduced the usage of erythropoietin stimulating agents (ESAs) during hemodialysis by 37.1% while maintaining iron balance and maximizing iron delivery.



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter